Wall Street Zen cut shares of SeaStar Medical (NASDAQ:ICU – Free Report) from a hold rating to a sell rating in a research report released on Saturday morning,Wall Street Zen reports.
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of SeaStar Medical in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SeaStar Medical has an average rating of “Hold” and an average target price of $8.00.
Check Out Our Latest Analysis on ICU
SeaStar Medical Stock Performance
SeaStar Medical (NASDAQ:ICU – Get Free Report) last announced its earnings results on Wednesday, November 11th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.08). SeaStar Medical had a negative return on equity of 199.99% and a negative net margin of 678.24%. The company had revenue of $0.64 million for the quarter, compared to analyst estimates of $0.50 million. Equities analysts anticipate that SeaStar Medical will post -3.66 earnings per share for the current year.
About SeaStar Medical
SeaStar Medical Holding Corp. is a medical technology company developing extracorporeal therapies intended to address harmful inflammation in patients with critical illnesses. Its approach uses the Selective Cytopheretic Device (SCD), which processes blood outside the body and is designed to target activated immune cells associated with inflammation. The company’s lead product, QUELIMMUNE, is an SCD-based therapy for certain pediatric patients with acute kidney injury and sepsis or a septic condition who require continuous kidney replacement therapy.
Further Reading
- Five stocks we like better than SeaStar Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.
